Christopher B. Jones
Christopher B. Jones, MD is a medical oncologist and hematologist in Golden, Colorado. Dr. Jones is a member of the Division of Oncology and Department of Medicine at National Jewish Health.
Department of Medicine
Western Hematology-Oncology
Division of Oncology
Specialties and ConditionsSpecialties & Conditions
Research AreasResearch Areas
  • Medical Oncology

Special Interests

I am a clinical hematology/oncology physician. I see all types of hematologic disorders and every type of cancer. I am interested in cooperative group oncology clinical trials to promote best practice in oncology to achieve optimal results.


University of Miami School of Medicine, Miami, FL,
Tripler Army Medical Center, Tripler, HI, Internal Medicine
Brooke Army Medical Center, Ft. Sam Houston, TX, Hematology/Oncology

Awards & Recognition

2005-2006: UTHSCA Outstanding Faculty Award for 3rd year Medical Student
2005: Bronze Star, Operation Iraqi Freedom II
2000: William J Uphouse Award for most compassionate physician

Board Certification

2003: Medical Oncology
2003: Hematology
2000: Internal Medicine

Professional Memberships

American Society Hematology


Schwartz Garry H and Jones Christopher B. et al. A Phase I and Pharmacokinetic Study of Non-polyglutamatible Thymidylate Synthase Inhibitor ZD9331 and Docetaxel in Patients with Advanced Solid Malignancies. Investigational New Drugs 22: 437-448, 2004.

Mita AC, Hammond LA, Jones CB et al. Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors. Clinical Cancer Research. 12: 5207-5215, 2006.

R.F. Setlik, G. Preston, C.B Jones et al. A Phase I Study of the Effects of Hepatic Impairment on the Pharmacokinetic (PK) and Safety of Satraplatin in Patients with Refractory Non-Hematologic Cancer. ASCO Clinical Proceedings, Abstract #2045, 2006

Shumway NM, Jones CB, and Terrazzino S. Randomized pilot study comparing aprepitant to olanzapine for treatment of chemotherapy-induced nausea and vomiting. ASCO Clinical Proceedings, Abstract 9633, 2009

Teaching & Professional Positions

2013-2015: Levine Cancer Institute, Leukemia Committee
2013-2015: Levine Cancer Institute, Upper/Lower GI Cancer Committee
2013-2015: Levine Cancer Institute, Genetic Committee
2007-2008: Chief, Hematology/Oncology Services, Brooke Army Medical Center
2006-2008: Assistant Program Director, SAUSWEC Hematology/Oncology Fellowship
2004-2005: Chief Medical Services, 115th Field Hospital


Spanish, Italian

Ask a Question through Patient Portal

Sign in to your My National Jewish Health patient portal account to communicate with your care team, manage appointments, and more. Create an Account

Contact Information

  • Office: 303.650.4042 or 303.232.0602
  • Fax: 303.650.4046 or 303.988.8750
  • Alternate: 877.225.5654



  • Western Hematology Oncology
    400 Indiana Street Red Rocks Medical Center #230
    Golden, CO 80401

Patient Ratings

The Patient Rating score is an average of all responses to care provider related questions on our independent rating system, the Press Ganey Patient Satisfaction Survey. This survey is about the patient care experience and does not address crucial characteristics like medical decision-making, prescribing the best therapy, and patient outcomes.

Responses are measured on a scale of 1 to 5, with 5 being the best score. Learn more about our patient satisfaction survey.


Comments are collected in our Press Ganey Patient Satisfaction Surveys. Patients are de-identified to protect confidentiality and patient privacy. Learn more about our patient satisfaction survey.